Basilea Pharmaceutica AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 147
- Market Cap
- $676.7M
- Website
- http://www.basilea.com
Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 250
- Registration Number
- NCT00309621
- Locations
- 🇩🇪
Abt. Klinische Sozialmedizin, Heidelberg, Germany
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2012-07-26
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 784
- Registration Number
- NCT00228982
Ceftobiprole in Hospital Acquired Pneumonia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 106
- Registration Number
- NCT00229008
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-07-26
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 828
- Registration Number
- NCT00210899
Ceftobiprole in Hospital Acquired Pneumonia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 781
- Registration Number
- NCT00210964
Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 300
- Registration Number
- NCT00124436
- Locations
- 🇩🇪
Thomas Ruzicka, Düsseldorf, Germany
Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 1035
- Registration Number
- NCT00124475
- Locations
- 🇩🇪
Thomas Ruzicka, MD, Düsseldorf, Germany
© Copyright 2024. All Rights Reserved by MedPath